The Zhitong Finance App learned that after the US Food and Drug Administration (FDA) decided to remove Lilly's (LLY.US)'s Tirzepatide (Tirzepatide) from the drug shortage list, a lawsuit against this delisting measure triggered a rise in Hims & Hers Health (HIMS.US) trading on Monday, closing 9.68% higher. As a result of this lawsuit, the FDA is now reconsidering delisting. Tesipatide is sold under the names Mounjaro and Zepbound and is used to treat type 2 diabetes and weight loss, respectively.

Zhitongcaijing · 10/15 01:57
The Zhitong Finance App learned that after the US Food and Drug Administration (FDA) decided to remove Lilly's (LLY.US)'s Tirzepatide (Tirzepatide) from the drug shortage list, a lawsuit against this delisting measure triggered a rise in Hims & Hers Health (HIMS.US) trading on Monday, closing 9.68% higher. As a result of this lawsuit, the FDA is now reconsidering delisting. Tesipatide is sold under the names Mounjaro and Zepbound and is used to treat type 2 diabetes and weight loss, respectively.